| 摘要 |
The present invention relates to a pharmaceutical composition for preventing and treating eye diseases, containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial growth factor (anti-VEGF) preparation are fused. More particularly, the present invention relates to: a pharmaceutical composition for preventing and treating eye diseases, containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-VEGF preparation are fused, to a method for producing an anti-VEGF preparation, which overcomes resistance and has improved efficacy, the method comprising the steps of transforming a host cell with a recombinant vector containing a nucleic acid sequence coding for a fusion protein in which a tissue-penetrating peptide and an anti-VEGF preparation are fused, culturing the cell, and recovering a fusion protein from the cell; a method for treating eye diseases, comprising administering an effective dose of the fusion protein, according to the present invention, to a subject in need thereof; and a use for producing a preparation for treating eye diseases, containing the fusion protein, according to the present invention, as an active ingredient. Compared to conventional anti-VEGF preparations, the composition according to the present invention is considered to have improved efficacy and be able to be used for treating patients having drug resistance, by inhibiting various growth factors related to new blood vessels, besides VEGF, and by decreasing pericyte coverage. In addition, since drug delivery ability into the choroid tissue is improved when performing an intraocular injection, the composition can be developed into eye drops by reducing an administered dosage or extending an administration cycle, and by improving ocular penetrability. |
